Epidermal growth factor receptor antibody and application thereof
The invention provides an epidermal growth factor receptor antibody and application thereof. The heavy chain amino acid sequence of the epidermal growth factor receptor antibody is shown as SEQ ID NO:1, and the light chain amino acid sequence is shown as SEQ ID NO:2. By adopting the epidermal growth...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LIANG JUNQING DING GUOYUAN FENG WEI DAOHONG CHEN GUO ZHIFANG CAO NAJING YAO BING HOU BIN LI WENYAN CHEN MENG SONG YANFEI WANG ZHIXIN LI HUIXIN KANG NING |
| description | The invention provides an epidermal growth factor receptor antibody and application thereof. The heavy chain amino acid sequence of the epidermal growth factor receptor antibody is shown as SEQ ID NO:1, and the light chain amino acid sequence is shown as SEQ ID NO:2. By adopting the epidermal growth factor receptor antibody, on the basis of keeping high target affinity and low immunogenicity of ahumanized antibody, the affinity of relevant receptors (Fc RIII and FcRn) are improved, the function of an activation cancer inhibition immune cell is improved remarkably, and the in-vitro/in-vivo anti-tumor effect is enhanced. As proved by experiments, the in-vitro cancer cell killing activity is improved by 4 times, the in-vivo anti-cancer efficacy is improved by 60 percent, and the bioavailability is improved. The anti-cancer efficacy of the epidermal growth factor receptor antibody is expected to exceed those of first and second generations of antibodies (including a large number of biosimilar antibodies under stu |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN109306010A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN109306010A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN109306010A3</originalsourceid><addsrcrecordid>eNrjZHB0LchMSS3KTcxRSC_KLy_JUEhLTC7JL1IoSk1OLQAxEvNKMpPyUyqBjBSFxIKCnMzkxJLM_DyFkozUotT8NB4G1rTEnOJUXijNzaDo5hri7KGbWpAfn1pckJicmpdaEu_sZ2hgaWxgZmBo4GhMjBoAO3syDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Epidermal growth factor receptor antibody and application thereof</title><source>esp@cenet</source><creator>LIANG JUNQING ; DING GUOYUAN ; FENG WEI ; DAOHONG CHEN ; GUO ZHIFANG ; CAO NAJING ; YAO BING ; HOU BIN ; LI WENYAN ; CHEN MENG ; SONG YANFEI ; WANG ZHIXIN ; LI HUIXIN ; KANG NING</creator><creatorcontrib>LIANG JUNQING ; DING GUOYUAN ; FENG WEI ; DAOHONG CHEN ; GUO ZHIFANG ; CAO NAJING ; YAO BING ; HOU BIN ; LI WENYAN ; CHEN MENG ; SONG YANFEI ; WANG ZHIXIN ; LI HUIXIN ; KANG NING</creatorcontrib><description>The invention provides an epidermal growth factor receptor antibody and application thereof. The heavy chain amino acid sequence of the epidermal growth factor receptor antibody is shown as SEQ ID NO:1, and the light chain amino acid sequence is shown as SEQ ID NO:2. By adopting the epidermal growth factor receptor antibody, on the basis of keeping high target affinity and low immunogenicity of ahumanized antibody, the affinity of relevant receptors (Fc RIII and FcRn) are improved, the function of an activation cancer inhibition immune cell is improved remarkably, and the in-vitro/in-vivo anti-tumor effect is enhanced. As proved by experiments, the in-vitro cancer cell killing activity is improved by 4 times, the in-vivo anti-cancer efficacy is improved by 60 percent, and the bioavailability is improved. The anti-cancer efficacy of the epidermal growth factor receptor antibody is expected to exceed those of first and second generations of antibodies (including a large number of biosimilar antibodies under stu</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190205&DB=EPODOC&CC=CN&NR=109306010A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190205&DB=EPODOC&CC=CN&NR=109306010A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LIANG JUNQING</creatorcontrib><creatorcontrib>DING GUOYUAN</creatorcontrib><creatorcontrib>FENG WEI</creatorcontrib><creatorcontrib>DAOHONG CHEN</creatorcontrib><creatorcontrib>GUO ZHIFANG</creatorcontrib><creatorcontrib>CAO NAJING</creatorcontrib><creatorcontrib>YAO BING</creatorcontrib><creatorcontrib>HOU BIN</creatorcontrib><creatorcontrib>LI WENYAN</creatorcontrib><creatorcontrib>CHEN MENG</creatorcontrib><creatorcontrib>SONG YANFEI</creatorcontrib><creatorcontrib>WANG ZHIXIN</creatorcontrib><creatorcontrib>LI HUIXIN</creatorcontrib><creatorcontrib>KANG NING</creatorcontrib><title>Epidermal growth factor receptor antibody and application thereof</title><description>The invention provides an epidermal growth factor receptor antibody and application thereof. The heavy chain amino acid sequence of the epidermal growth factor receptor antibody is shown as SEQ ID NO:1, and the light chain amino acid sequence is shown as SEQ ID NO:2. By adopting the epidermal growth factor receptor antibody, on the basis of keeping high target affinity and low immunogenicity of ahumanized antibody, the affinity of relevant receptors (Fc RIII and FcRn) are improved, the function of an activation cancer inhibition immune cell is improved remarkably, and the in-vitro/in-vivo anti-tumor effect is enhanced. As proved by experiments, the in-vitro cancer cell killing activity is improved by 4 times, the in-vivo anti-cancer efficacy is improved by 60 percent, and the bioavailability is improved. The anti-cancer efficacy of the epidermal growth factor receptor antibody is expected to exceed those of first and second generations of antibodies (including a large number of biosimilar antibodies under stu</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB0LchMSS3KTcxRSC_KLy_JUEhLTC7JL1IoSk1OLQAxEvNKMpPyUyqBjBSFxIKCnMzkxJLM_DyFkozUotT8NB4G1rTEnOJUXijNzaDo5hri7KGbWpAfn1pckJicmpdaEu_sZ2hgaWxgZmBo4GhMjBoAO3syDw</recordid><startdate>20190205</startdate><enddate>20190205</enddate><creator>LIANG JUNQING</creator><creator>DING GUOYUAN</creator><creator>FENG WEI</creator><creator>DAOHONG CHEN</creator><creator>GUO ZHIFANG</creator><creator>CAO NAJING</creator><creator>YAO BING</creator><creator>HOU BIN</creator><creator>LI WENYAN</creator><creator>CHEN MENG</creator><creator>SONG YANFEI</creator><creator>WANG ZHIXIN</creator><creator>LI HUIXIN</creator><creator>KANG NING</creator><scope>EVB</scope></search><sort><creationdate>20190205</creationdate><title>Epidermal growth factor receptor antibody and application thereof</title><author>LIANG JUNQING ; DING GUOYUAN ; FENG WEI ; DAOHONG CHEN ; GUO ZHIFANG ; CAO NAJING ; YAO BING ; HOU BIN ; LI WENYAN ; CHEN MENG ; SONG YANFEI ; WANG ZHIXIN ; LI HUIXIN ; KANG NING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN109306010A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2019</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>LIANG JUNQING</creatorcontrib><creatorcontrib>DING GUOYUAN</creatorcontrib><creatorcontrib>FENG WEI</creatorcontrib><creatorcontrib>DAOHONG CHEN</creatorcontrib><creatorcontrib>GUO ZHIFANG</creatorcontrib><creatorcontrib>CAO NAJING</creatorcontrib><creatorcontrib>YAO BING</creatorcontrib><creatorcontrib>HOU BIN</creatorcontrib><creatorcontrib>LI WENYAN</creatorcontrib><creatorcontrib>CHEN MENG</creatorcontrib><creatorcontrib>SONG YANFEI</creatorcontrib><creatorcontrib>WANG ZHIXIN</creatorcontrib><creatorcontrib>LI HUIXIN</creatorcontrib><creatorcontrib>KANG NING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LIANG JUNQING</au><au>DING GUOYUAN</au><au>FENG WEI</au><au>DAOHONG CHEN</au><au>GUO ZHIFANG</au><au>CAO NAJING</au><au>YAO BING</au><au>HOU BIN</au><au>LI WENYAN</au><au>CHEN MENG</au><au>SONG YANFEI</au><au>WANG ZHIXIN</au><au>LI HUIXIN</au><au>KANG NING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Epidermal growth factor receptor antibody and application thereof</title><date>2019-02-05</date><risdate>2019</risdate><abstract>The invention provides an epidermal growth factor receptor antibody and application thereof. The heavy chain amino acid sequence of the epidermal growth factor receptor antibody is shown as SEQ ID NO:1, and the light chain amino acid sequence is shown as SEQ ID NO:2. By adopting the epidermal growth factor receptor antibody, on the basis of keeping high target affinity and low immunogenicity of ahumanized antibody, the affinity of relevant receptors (Fc RIII and FcRn) are improved, the function of an activation cancer inhibition immune cell is improved remarkably, and the in-vitro/in-vivo anti-tumor effect is enhanced. As proved by experiments, the in-vitro cancer cell killing activity is improved by 4 times, the in-vivo anti-cancer efficacy is improved by 60 percent, and the bioavailability is improved. The anti-cancer efficacy of the epidermal growth factor receptor antibody is expected to exceed those of first and second generations of antibodies (including a large number of biosimilar antibodies under stu</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN109306010A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE |
| title | Epidermal growth factor receptor antibody and application thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A28%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LIANG%20JUNQING&rft.date=2019-02-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN109306010A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |